Specialized cell component therapy

Transfusion therapy for patients critically Ill with cancer

Patients with cancer receive antineoplastic therapy that affect their ability to produce and maintain circulating levels of blood cells at any given time. Frequent and varied transfusion requirements necessitate a highly developed and specialized practice of blood component therapy in cancer care. In this article, the author discusses factors affecting the selection of blood components and the influence that expert critical care nurses can contribute to safe and effective transfusion therapy. Administration of leukocyte-poor or cytomegalovirus-negative erythrocytes, pheresed platelets, and granulocyte transfusions are described.

Allogeneic bone marrow transplantation

From highly investigational to standardized therapy, allogeneic BMT has established its role in the treatment of selected diseases. Continued refinements in bone marrow transplantation will increase the number of potential candidates, reduce associated risks, and improve disease-free survival rates. With further exploration into its efficacy, allogeneic BMT will bring new challenges and opportunities for patients, families, and health care providers.

Meeting the challenge of infection: a case study

Infection is the most critical complication of cancer. A case study is presented that describes an adolescent with acute lymphocytic leukemia. He experienced multiple complications due to infection. Both new and standard therapies were required for the treatment and prevention of infections. A discussion of the rationale for various aspects of his care is presented.